Earnings
Alcon Defends $250 Million–$400 Million Retinal Treatment Forecast — Surgery Access Sets The Pace
Neurotech is expected to add 0.75–1 percentage point to companywide sales growth in 2027, with some near-term margin pressure.
Alcon (ALC) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Neurotech is expected to add 0.75–1 percentage point to companywide sales growth in 2027, with some near-term margin pressure.
SEC Filings
The eye-care company increased expected annual efficiency savings to approximately $130 million from approximately $100 million.